Home > Publications Database > CSF oligoclonal IgG bands are not associated with ALS progression and prognosis. > print

001     258098
005     20231004134643.0
024 7 _ |a 10.3389/fneur.2023.1170360
|2 doi
024 7 _ |a pmid:37213901
|2 pmid
024 7 _ |a pmc:PMC10196068
|2 pmc
024 7 _ |a altmetric:147555265
|2 altmetric
037 _ _ |a DZNE-2023-00560
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Klose, Veronika-Felicitas
|0 P:(DE-2719)9001084
|b 0
|e First author
|u dzne
245 _ _ |a CSF oligoclonal IgG bands are not associated with ALS progression and prognosis.
260 _ _ |a Lausanne
|c 2023
|b Frontiers Research Foundation
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1686044356_28876
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Amyotrophic Lateral Sclerosis (ALS) is characterized by progressive motoneuron degeneration through cell autonomous and non-cell autonomous mechanisms; and the involvement of the innate and adaptive immune system has been hypothesized based on human and murine model data. We have explored if B-cell activation and IgG responses, as detected by IgG Oligoclonal bands (OCB) in serum and cerebrospinal fluid, were associated with ALS or with a subgroup of patients with distinct clinical features.IgG OCB were determined in patients affected by ALS (n=457), Alzheimer Disease (n=516), Mild Cognitive Impairment (n=91), Tension-type Headache (n=152) and idiopathic Facial Palsy (n=94). For ALS patients, clinico-demographic and survival data were prospectively collected in the Register Schabia.The prevalence of IgG OCB is comparable in ALS and the four neurological cohorts. When the OCB pattern was considered (highlighting either intrathecal or systemic B-cells activation), no effect of OCB pattern on clinic-demographic parameters and overall. ALS patients with intrathecal IgG synthesis (type 2 and 3) were more likely to display infectious, inflammatory or systemic autoimmune conditions.These data suggest that OCB are not related to ALS pathophysiology but rather are a finding possibly indicative a coincidental infectious or inflammatory comorbidity that merits further investigation.
536 _ _ |a 352 - Disease Mechanisms (POF4-352)
|0 G:(DE-HGF)POF4-352
|c POF4-352
|f POF IV
|x 0
536 _ _ |a 354 - Disease Prevention and Healthy Aging (POF4-354)
|0 G:(DE-HGF)POF4-354
|c POF4-354
|f POF IV
|x 1
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 2
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a age of onset
|2 Other
650 _ 7 |a amyotrophic lateral sclerosis
|2 Other
650 _ 7 |a cerebrospinal fluid
|2 Other
650 _ 7 |a intrathecal synthesis
|2 Other
650 _ 7 |a oligoclonal bands
|2 Other
650 _ 7 |a survival
|2 Other
700 1 _ |a Jesse, Sarah
|0 P:(DE-2719)9001441
|b 1
|u dzne
700 1 _ |a Lewerenz, Jan
|b 2
700 1 _ |a Kassubek, Jan
|0 P:(DE-2719)9001967
|b 3
|u dzne
700 1 _ |a Dorst, Johannes
|0 P:(DE-2719)9001951
|b 4
|u dzne
700 1 _ |a Tumani, Hayrettin
|0 P:(DE-2719)9002007
|b 5
|u dzne
700 1 _ |a Ludolph, Albert C
|0 P:(DE-2719)2812633
|b 6
|u dzne
700 1 _ |a Roselli, Francesco
|0 P:(DE-2719)2812851
|b 7
|e Last author
|u dzne
773 _ _ |a 10.3389/fneur.2023.1170360
|g Vol. 14, p. 1170360
|0 PERI:(DE-600)2564214-5
|p 1170360
|t Frontiers in neurology
|v 14
|y 2023
|x 1664-2295
856 4 _ |u https://pub.dzne.de/record/258098/files/DZNE-2023-00560%20SUP.TIF
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/258098/files/DZNE-2023-00560.pdf
856 4 _ |u https://pub.dzne.de/record/258098/files/DZNE-2023-00560%20SUP.gif?subformat=icon
|x icon
856 4 _ |u https://pub.dzne.de/record/258098/files/DZNE-2023-00560%20SUP.jpg?subformat=icon-1440
|x icon-1440
856 4 _ |u https://pub.dzne.de/record/258098/files/DZNE-2023-00560%20SUP.jpg?subformat=icon-180
|x icon-180
856 4 _ |u https://pub.dzne.de/record/258098/files/DZNE-2023-00560%20SUP.jpg?subformat=icon-640
|x icon-640
856 4 _ |u https://pub.dzne.de/record/258098/files/DZNE-2023-00560.pdf?subformat=pdfa
|x pdfa
|y OpenAccess
909 C O |o oai:pub.dzne.de:258098
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 0
|6 P:(DE-2719)9001084
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 1
|6 P:(DE-2719)9001441
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 3
|6 P:(DE-2719)9001967
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 4
|6 P:(DE-2719)9001951
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 5
|6 P:(DE-2719)9002007
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 6
|6 P:(DE-2719)2812633
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 7
|6 P:(DE-2719)2812851
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-352
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Disease Mechanisms
|x 0
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-354
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Disease Prevention and Healthy Aging
|x 1
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 2
914 1 _ |y 2023
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2022-11-18
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2021-05-11T13:11:28Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2021-05-11T13:11:28Z
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2022-11-18
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2022-11-18
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2022-11-18
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b FRONT NEUROL : 2022
|d 2023-08-23
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-08-23
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-08-23
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2023-08-23
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2021-05-11T13:11:28Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-08-23
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-08-23
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2023-08-23
920 1 _ |0 I:(DE-2719)1910001
|k AG Roselli
|l Metabolic Changes
|x 0
920 1 _ |0 I:(DE-2719)1910005
|k AG Zhan ; AG Zhan
|l Neuroepidemiology
|x 1
920 1 _ |0 I:(DE-2719)5000077
|k Clinical Study Center ; Clinical Study Center Ulm
|l Clinical Study Center Ulm
|x 2
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1910001
980 _ _ |a I:(DE-2719)1910005
980 _ _ |a I:(DE-2719)5000077
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21